Antifactor Xa activity and antithrombotic activity in rats of structural analogues of the minimum antithrombin III binding sequence: discovery of compounds with a longer duration of action than of the natural pentasaccharide
- PMID: 2068564
Antifactor Xa activity and antithrombotic activity in rats of structural analogues of the minimum antithrombin III binding sequence: discovery of compounds with a longer duration of action than of the natural pentasaccharide
Abstract
The total chemical synthesis of a series of structural analogues of the so-called natural AT III binding pentasaccharide together with the natural pentasaccharide itself has been accomplished. The structural analogues all contain an extra 3-O-sulfate group on glucosamine residue H of the pentasaccharide, some carry additional 3 or 4-O-sulfate groups on glucosamine residue D. All these structural analogues elicit a higher specific anti-Factor Xa activity than the natural pentasaccharide (700 anti-Factor Xa U/kg). The structural analogue carrying only an additional 3-O-sulfate on glucosamine unit H (Org 31550) has the highest specific activity (1230 anti-Factor Xa U/kg). The increased specific activity is presumably attributed to the stronger binding to AT III. All structural analogues have a prolonged duration of action of the plasma anti-Factor Xa activity. (T1/2, approximately 9 hours) compared with that of the natural pentasaccharide (T1/2, approximately 5 hours) after single intravenous administration of 600 anti-Factor Xa U/kg. All structural analogues exert dose-dependent antithrombotic activity in a rat stasis thrombosis model after intravenous administration. On an anti-Factor Xa basis, the compounds have the same potency as the natural pentasaccharide (ED50s are 35 to 55 anti-factor Xa U/kg). Of two structural analogues (Org 31550 and Org 31706), the time course of antithrombotic activity was assessed in the same model after subcutaneous administration of 600 anti-Factor Xa U/kg. The duration of antithrombotic activity of these compounds was four to five times longer than that of the natural pentasaccharide.
Similar articles
-
Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats.Thromb Haemost. 1990 Apr 12;63(2):265-70. Thromb Haemost. 1990. PMID: 2363127
-
Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.Thromb Haemost. 2002 Feb;87(2):238-44. Thromb Haemost. 2002. PMID: 11858483
-
Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540).J Med Chem. 1997 May 23;40(11):1600-7. doi: 10.1021/jm960726z. J Med Chem. 1997. PMID: 9171870
-
From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile.Thromb Haemost. 2009 Nov;102(5):804-10. doi: 10.1160/TH09-01-0063. Thromb Haemost. 2009. PMID: 19888512 Review.
-
A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?Angew Chem Int Ed Engl. 2004 Jun 14;43(24):3118-33. doi: 10.1002/anie.200300640. Angew Chem Int Ed Engl. 2004. PMID: 15199558 Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical